Pork firm Smithfield sets up organ supply unit for regenerative meds sector

By Staff reporter

- Last updated on GMT

Related tags Medicine Pharmacology

Smithfield Foods Inc. has tasked a new bioscience unit with turning byproducts from its pork business into supplies for regenerative meds and drug firms.

The firm – which is part of Chinese meat processing organistion WH Group – already sells pork byproducts to pharmaceutical companies which use them to make treatments for conditions like indigestion, hypothyroidism and deep vein thrombosis

The bioscience unit will build on this established supply business according to Smithfield, which said the aim is to explore methods and technologies for addressing concerns such as tissue regeneration and the availability of viable human organs for transplantation.

Military applications

Smithfield Bioscience already has joined a number of projects.

The firm has teamed up with the US Government​ backed Advanced Regenerative Manufacturing Institute (AMRI) and a consortium of academics to develop technologies that can produce replacement tissues for soldiers injured in combat.

Smithfield Bioscience has also partnered with researchers developing immunotherapies at Harvard Medical School and Columbia University.

Courtney Stanton, vice president of the Smithfield Bioscience said the firm “is well-positioned to help the US medical and pharmaceutical industry achieve significant, scalable developments in biologics."

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more